100 Clinical Results associated with Parvus Therapeutics U.S., Inc.
0 Patents (Medical) associated with Parvus Therapeutics U.S., Inc.
AbbVie could add a new modality to its flagship immunology portfolio, thanks to a deal with Parvus Therapeutics announced Wednesday. The pharma gained an exclusive, worldwide option to develop and commercialise inflammatory bowel disease (IBD) therapies developed with Parvus’ Treg immune tolerization platform technology. The biotech’s therapeutics, dubbed Navacims, present multivalent peptide-MHCs to T-cells, which triggers their expansion and differentiation into antigen-specific Tregs to induce organ-specific immune tolerance without compromising normal immunity to infections and cancer. The deal’s terms were not disclosed. In addition to an upfront payment, Parvus is eligible for a potential equity investment, as well as milestones and royalties. Parvus also has an ongoing partnership with Roche’s Genentech unit to develop Navacim therapeutics for autoimmune diseases, which could pay out more than $800 million.
License out/inImmunotherapy
Plus, news about Aquestive Therapeutics and Cybin:
AbbVie enlists Parvus Therapeutics for IBD pact:
AbbVie will have the option to develop and commercialize Parvus’ therapies for inflammatory bowel diseases (IBD). Parvus’ therapies trigger T cells to grow and turn into regulatory T cells — a specialized type of T cell that can suppress the immune system.
The
deal
adds another pipeline option to AbbVie’s IBD franchise, which includes Rinvoq and Skyrizi. And it adds to Parvus’ list of pharma collaborators, which include Novartis and Roche’s Genentech. Financial details of the licensing deal were not disclosed, though Parvus could receive a potential equity investment from AbbVie.
— Lei Lei Wu
License out/inCell TherapyImmunotherapy
100 Deals associated with Parvus Therapeutics U.S., Inc.
100 Translational Medicine associated with Parvus Therapeutics U.S., Inc.